- Conditions
- Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer, Glioblastoma Multiforme, GBM, Brain Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Prostate Cancer, Melanoma Recurrent, Prostate Cancer Metastatic, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma
- Interventions
- ST101, Temozolomide, Radiation
- Drug · Radiation
- Lead sponsor
- Sapience Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 7
- States / cities
- San Francisco, California • Denver, Colorado • Warrenville, Illinois + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 337
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cardiac Failure, Renal Failure, Kidney Failure
- Interventions
- Protocolized Diuretic Strategy
- Drug
- Lead sponsor
- Kelly V. Liang, MD
- Other
- Eligibility
- 21 Years and older · Male only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Human Immunodeficiency Virus
- Interventions
- Lenacapavir
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Kidney Transplantation
- Interventions
- Mycophenolic Acid, Standard of Care: CNI and MPA
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Major Depressive Disorder
- Interventions
- Transcranial Magnetic Stimulation (TMS) - Fully Individualized iTBS, Transcranial Magnetic Stimulation (TMS) - targeted-iTBS, Transcranial Magnetic Stimulation (TMS) - Standard-iTBS
- Device
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Breast Cancer
- Interventions
- chemotherapy
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 624 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2017
- U.S. locations
- 296
- States / cities
- Anniston, Alabama • Anchorage, Alaska • Jonesboro, Arkansas + 210 more
- Conditions
- Glioma
- Interventions
- Biospecimen Collection, Dasatinib, Fisetin, Magnetic Resonance Imaging, Patient Observation, Positron Emission Tomography, Quercetin, Temozolomide, Topoisomerase-1 Inhibitor LMP744, Single Agent Therapy
- Procedure · Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Kidney Transplantation, Mycophenolate Mofetil
- Interventions
- Mycophenolate Mofetil (MMF) Maintenance Group, Mycophenolate Mofetil (MMF) Withdrawal Group
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2031
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Pain, Postoperative
- Interventions
- TiZANidine 2 MG Oral Capsule
- Drug
- Lead sponsor
- Rothman Institute Orthopaedics
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Lymphoma
- Interventions
- personalized medication log, standard of care, questionnaires, Cognitive Interview
- Other · Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Ovarian Cancer
- Interventions
- DCE-MRI scans
- Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Patients Scheduled for Colonoscopy
- Interventions
- Use of Linaclotide as a single agent Colonoscopy prep
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Graft Vs Host Disease
- Interventions
- antimetabolite
- Drug
- Lead sponsor
- Methodist Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Hematologic Neoplasms, Thrombocytopenia, Anticoagulants, Platelet Aggregation Inhibitors
- Interventions
- Hold, Prophylactic dose antithrombotic, Change antithrombotic Drug, Change platelet transfusion threshold, Full dose antithrombotics, Mechanical measures, Intermediate dose antithrombotic
- Drug · Biological · Device
- Lead sponsor
- Maastricht University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Multiple Sclerosis, Healthy
- Interventions
- Blood draw
- Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Usual Clinical Practice, Shared Medical Decision Making
- Behavioral
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- 11 Years to 17 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Kidney Failure, Chronic
- Interventions
- Everolimus
- Drug
- Lead sponsor
- Ashtar Chami
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- NSCLC, Locally Advanced
- Interventions
- Cemiplimab, Fianlimab, Radiotherapy, Platinum Doublet Chemotherapy (PDC)
- Drug · Radiation
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
- Interventions
- Plerixafor
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Multiple Myeloma
- Interventions
- Filgrastim, Bortezomib, Carfilzomib, Dexamethasone, Cyclophosphamide, Thalidomide, Lenalidomide, Pomalidomide
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Fanconi Anemia, Severe Marrow Failure, Myelodysplastic Syndrome (MDS), Acute Myelogenous Leukemia (AML)
- Interventions
- Busulfan, Cyclophosphamide, Fludarabine, rabbit ATG, G-CSF, Peripheral blood stem cell
- Drug · Biological
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 3 Months and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2028
- U.S. locations
- 3
- States / cities
- New York, New York • Cincinnati, Ohio • Seattle, Washington
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- Nilotinib, Best Supportive Care (BSC) +/- imatinib or sunitinib
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 8 more
- Conditions
- Hypertension
- Interventions
- olmesartan medoxomil, Olmesartan medoxomil plus Hydrochlorothiazide
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Searcy, Arkansas + 24 more
- Conditions
- Radial Head Fracture
- Interventions
- Outpatient physical therapy in addition to standard follow-up visits, Home exercises in addition to standard follow-up visits
- Procedure · Behavioral
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York